WO1992005250A1 - Prolonging expression of polynucleotides introduced into a cell - Google Patents
Prolonging expression of polynucleotides introduced into a cell Download PDFInfo
- Publication number
- WO1992005250A1 WO1992005250A1 PCT/US1991/006885 US9106885W WO9205250A1 WO 1992005250 A1 WO1992005250 A1 WO 1992005250A1 US 9106885 W US9106885 W US 9106885W WO 9205250 A1 WO9205250 A1 WO 9205250A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- cell
- dna
- complex
- hepatocytes
- Prior art date
Links
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 82
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 77
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 77
- 230000014509 gene expression Effects 0.000 title claims abstract description 49
- 239000011230 binding agent Substances 0.000 claims abstract description 21
- 230000009870 specific binding Effects 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 33
- XJGBDJOMWKAZJS-UHFFFAOYSA-N Nafenoic Acid Chemical group C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C2=CC=CC=C2CCC1 XJGBDJOMWKAZJS-UHFFFAOYSA-N 0.000 claims description 30
- 229950006205 nafenopin Drugs 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 23
- 210000003494 hepatocyte Anatomy 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 14
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 14
- 238000012753 partial hepatectomy Methods 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000002085 persistent effect Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 8
- 239000002831 pharmacologic agent Substances 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 108010002913 Asialoglycoproteins Proteins 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 230000000536 complexating effect Effects 0.000 claims description 3
- 230000012202 endocytosis Effects 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims 1
- 241000905957 Channa melasoma Species 0.000 claims 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 230000010076 replication Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 11
- 101150055766 cat gene Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 108010084541 asialoorosomucoid Proteins 0.000 description 7
- 108091092356 cellular DNA Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 206010019837 Hepatocellular injury Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101000930477 Mus musculus Albumin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 238000012752 Hepatectomy Methods 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 108010044715 asialofetuin Proteins 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Definitions
- a foreign gene can be targeted to, and expressed, in a cell in vivo.
- This can be accomplished using a soluble complex of DNA and a carrier system consisting of two linked components: 1) a polycation, e.g., poly-L-lysine, that can bind a polynucleotide in a strong but non-damaging interaction and 2) a ligand which can be targeted specifically to a cell surface molecule unique to the cell.
- a polycation e.g., poly-L-lysine
- a ligand which can be targeted specifically to a cell surface molecule unique to the cell.
- exogenous DNA introduced into a cell by this method can be transient. Although short-lived expression may be desirable for some applications of gene therapy, in many other applications, prolonged expression of the poly nucleotide would be required. There exists a need for a method of introducing DNA into cells in vivo so that expression of the DNA can be made to persist.
- This invention pertains to a method of introducing a polynucleotide into a target cell and causing expression of the introduced polynucleotide to persist in the cell.
- the polynucleotide is administered in vivo as a targeted polynucleotide complex which is specifically incorporated into the cell and the target cell is stimulated to replicate.
- Replication of the cell causes expression of the introduced polynucleotide to persist, as compared to the transient expression which can occur in the absence of stimulated replication.
- the targeted polynucleotide complex comprises the polynucleotide releasably (under intracellular conditions) complexed to a cell-specific binding agent which specifically binds a molecule on the surface of the target cell.
- the polynucleotide can be bound to the cell-specific binding agent through a polynucleotide-binding agent, such as a polycation, which is linked to the cell-specific binding agent.
- the binding agent for the cell surface component can be a ligand for a cellular surface receptor, preferably a cellular surface receptor which mediates internalization of ligands by endocytosis, or it can be a receptor, such as an antibody, for a cellular surface antigen.
- the targeted polynucleotide complex is preferably soluble in physiological fluids.
- the target cell can be stimulated to replicate by surgical or pharmacological means. For example, partial excision of regenerative organ or tissue which the cell constitutes can be performed to stimulate replication. Alternatively, a drug which stimulates cellular replication can be used.
- the method of this invention is useful in gene therapy and in other applications where prolonged expression of a polynucleotide introduced into a cell is desired.
- Figure 1 shows the time course of targeted gene expression.
- Groups of two rats were injected with asialoorosomucoid (AsOR)-poly-L-lysine-polynucleotide (CAT gene) complex and at daily intervals animals were killed, liver samples removed, homogenized and equal amounts of homogenate protein assayed for CAT activity.
- AsOR asialoorosomucoid
- CAT gene poly-L-lysine-polynucleotide
- Figure 2 shows the effect of partial hepatectomy on targeted CAT gene expression. Rats were injected with AsOR-poly-L-lysine-polynucleotide complex. A 66% partial hepatectomy was performed 30 minutes later, and at various time points livers were assayed for CAT activity.
- Figure 3 shows a Southern blot demonstrating the state of targeted DNA in livers 11 weeks after partial hepatectomy.
- DNA was extracted from livers, digested with restriction enzymes, and applied on an agarose gel electrophoresis together with palb-CAT standards as described below in the Exemplification. The samples were subsequently transferred to nitrocellulose and detected by hybridization to a 32 P _; L a ] De ⁇ e a AT cDNA robe .
- a polynucleotide into a target cell in vivo is brought about by administer ⁇ ing the polynucleotide in the form of a targeted complex.
- the targeted polynucleotide complex comprises polynucleotide linked releasably to a cell-specific binding agent which binds a surface component of the targeted cell.
- the polynucleotide complex is administered in vivo where it selectively binds to and is internalized by the cell.
- the polynucleotide is generally DNA. Typically it comprises a structural gene encoding the product to be expressed in the target cell and appropriate genetic regulatory elements (promoter, enhancer etc.) to regulate expression of the structural gene product in the target cell. These can be carried by a vector such as plasmid or a transposable genetic element.
- the polynucleotide complex can be made by binding the polynucleotide directly to the ligand.
- the polynucleotide is bound to the ligand through a polynucleotide-binding agent.
- the polynucleotide-binding agent is covalently bonded to the ligand.
- the polynucleotide-binding agent must be capable of complexing the polynucleotide so that the polynucleotide is released from the complex in a functional form after internalization within the cell.
- the bond should be extracellularly stable, i.e., of strength sufficient to prevent uncoupling of the polynucleotide extracellularly prior to cell internalization but it should be cleavable under appropriate conditions within the cell so the polynucleotide can be released intracellularly.
- the bond between the polynucleotide-binding component and the polynucleotide can be a non- covalent bond based on electrostatic attraction.
- Preferred polynucleotide-binding agents are polycations that bind to negatively charged polynucleotides. Positively charged polycations provide secure, tight complexing in a noncovalent manner to form soluble, targetable polynucleotide complexes.
- the bound polynucleotide is undamaged. Suitable polycations are polylysine, polyarginine, polyornithine, basic proteins such as histones, avidin, protamines and the like.
- non-covalent bonds that could be used consistent with linkage strategy include hydrogen bonding, hydrophobic bonding, electrost-cic bonding alone or in combination/as in: anti-polynucleotide antibodies bound to polynucleotide, and strepavidin or avidin binding to polynucleotide containing biotinylated nucleotides.
- the polynucleotide complex can contain more than one polynucleotide molecule.
- the ratio of polynucleotide to ligand-polynucleotide binding complex is from about 0.5 to about 1. The number may vary, depending upon factors such as the effect on solubility or capillary permeability of the complex.
- the cell-specific binding agent can be a ligand which binds to a surface receptor of the target cell or the binding agent can be a receptor or receptor ⁇ like molecule, such as an antibody, which binds a ligand (antigen) on the cell surface.
- the binding agent is a ligand for a cellular surface receptor which mediates internalization of the ligand by, for example, the process of endocytosis.
- the receptor-specific ligand can be a protein having functional groups that are exposed sufficiently to be recognized by the cell receptors.
- the receptor- specific ligand can also be a component of a biological organism such as a virus, or cells (bacterial, protozoan or mammalian) or artificial carriers such as liposomes.
- ligands will vary with the particular target cell. Glycoproteins having certain exposed terminal carbohydrate groups can be used although other ligands such as polypeptide hormones, also may be employed. For specific targeting to hepatocytes (liver cells), asialoglycoprotein (galactose- terminal) ligands are preferred. Examples of asialoglycoproteins include asialoorosomucoid, asialofetuin and desialylated vesicular stomatitis virus. These can be formed by chemical or enzymatic desialylation of those glycoproteins that possess terminal sialic acid and penultimate galactose residues.
- hepatocyte-targetable asialoglycoprotein ligands may be created by coupling lactose or other galactose terminal carbohydrates (e.g., arabinogalactan) to non-galactose-bearing proteins by reductive lactosamination.
- lactose or other galactose terminal carbohydrates e.g., arabinogalactan
- non-galactose-bearing proteins e.g., arabinogalactan
- cell-specific targeting to other (non-hepatic) cells can involve ligands such as mannose for macrophages (lymphoma) mannose-6-phosphate glycoproteins for fibroblasts (fibrosarcoma) , intrinsic factor - vitamin B12 for enterocytes and insulin for fat cells.
- the polynucleotide complex is soluble in physiological fluids.
- Soluble DNA complexes can be prepared with proteinaceous ligands and polycations as polynucleotide-binding agents.
- the polynucleotide complex is generally administered parenterally in a physiologically- acceptable vehicle, generally in an amount sufficient to saturate receptors of the target cell in vivo.
- the target cell can be stimulated to replicate either before or after (generally within 12 hours) administration of the polynucleotide.
- the target cell can be stimulated to replicate by surgical or pharmacological means.
- partial excision of a regenerative organ or tissue which are comprised of the cell can be performed to stimulate replication (regeneration).
- partial hepatectomy can be performed to stimulate replication of liver cells.
- Pharmacological agents which stimulate replication of the target cells such as nafenopin, galactosamine and carbon tetrachloride, or analogues thereof, may be used.
- Factors or hormones that stimulate replication may also be used.
- insulin and glucagon in combination can stimulate hepatocyte replication.
- Additional doses of the stimulant may be administered at various intervals after the initial administration (with or without the administration additional targeted polynucleotide complex) to prolong further the expression of the polynucleotide.
- the expression achieved by the method of this invention can peak at approximately 8 weeks after administration of the polynucleotide. Furthermore, expression can persist at significant levels for at least 4 months. An unusual feature of the persistent expression is the increase in the level of expression over time.
- This method of prolonging gene expression has value for gene therapy of inherited disorders of metabolism in man and animals.
- the prolongation of the foreign gene expression makes practical the periodic, but not too frequent, administration of a gene.
- replication of the targeted DNA increases the mass of the desired gene in the host. Therefore, stimulation of replication of recipient cells may obviate the need for readministration of the gene.
- Example 1 Persistent gene expression brought about by partial hepatectomy.
- Targetable polynucleotide Carrier To form a carrier system capable to being targeted specifically to hepatocytes, orosomucoid was isolated from pooled human serum (American Red Cross, Farmington, CT) (Whitehead, D.H., and Sammons, H.G. (1966) Biochim. Biophvs. Acta 124.:209-211) and desialylated with insolubilized neuraminidase (Type X-A, Sigma) to form asialoorosomucoid (AsOR)
- Plasmid Preparation - The palb-CAT construct was prepared by replacement of an SV40 early promoter by mouse albumin promoter (-330 to +10 base pairs) and enhancer sequences (-12 to -8.5 kilobases) (Pinkert, C.A., Ornitz, D.M., Brinster, R.L., and Palmiter, R.D. (1987) Genes & Dev. 1:268-276) in the plasmid MTBV.JT. The plasmid was cloned in Escherichia coli. isolated, and purified (Birnboim, H.C., and Doly, J. (1979) Nucleic Acids Res. 7:1513-1518).
- CAT insert was labeled with 32 P by nick translation (Maniatis, T., Fritsch, E.F., and Sambrook, J. (1982) Molecular Cloning; A Laboratory Manual, pp. 150-161, Cold Spring Harbor Laboratory, Cold Spring Harber, NY) .
- Targeted Gene Expression To assess targeted gene expression, female Sprague-Dawley rats (220-250 g) in groups of two were injected intravenously with 1 ml of saline containing 580 ⁇ g of palb-CAT DNA in the form of AsOR-poly-L-lysine-DNA complex or controls, and at daily intervals animals were killed and liver samples were removed and homogenized.
- FIG. 1 Targeted foreign gene expression as a function of time is shown in Figure 1, a representative assay for CAT gene expression.
- CAT activity was 10 units/g liver at 24 hours and 7.6 units/g 48 hours after injection. However, the expression was transient as activity declined to 4.6 units/g at 72 hours, and by 96 hours CAT activity was no longer detectable.
- lanes 1-3 contain palb-CAT plasmid, 0.01, 0.05, and 0.1 ⁇ g, respectively, linearized by digestion with Xbal which cuts the plasmid at a single site.
- Lane 4 shows the electrophoretic position of the CAT insert excised from the standard palb-CAT plasmid by BamHI.
- Lane 5 shows that cellular DNA from livers treated with the targetable DNA complex and analyzed 11 weeks after partial hepatectomy contained high molecular weight sequences that hybridized with the CAT cDNA probe. Digestion of this cellular DNA with BamHI, shown in lane 6, resulted in complete release of the CAT insert which migrated in a manner identical to the insert excised from standard palb-CAT plasmid (lane 4).
- Lanes 7-9 show that Xbal digestion of cellular DNA from livers treated with complex and analyzed 11 weeks post-partial hepatectomy resulted in the formation of some hybridizable fragments of lower molecular weight than the intact linear plasmid, but the majority of the hybridizable sequences remained present as DNA greater in size than the linear form of the plasmid. Restriction of cellular DNA by an enzyme that does not cut the plasmid, Bstell, shown in lanes 10-12, resulted in the formation of hybridizable fragments that were all greater in size than the palb-CAT plasmid.
- the plasmid, p9-12 albCAT containing the CAT gene driven by mouse albumin regulatory elements was complexed to our targetable DNA carrier system.
- nafenopin The hypolipidemic drug, nafenopin [2-methyl-2-p-(1,2,3,4-tetrahydro-1-na ⁇ hthy)- phenoxypropionic acid] , was chosen for study because of previous reports demonstrating that nafenopin is a potent stimulator of hepatocyte replication without causing hepatocellular damage.
- Our first objective was to determine the optimal time in which nafenopin should be administered in relation to injection of the DNA complex. To determine this, groups of rats, 200-250 gm, were pre-injected with nafenopin, 200mg/kg i.p., 12, 18 and 24 hours prior to the injection of complex or saline control.
- nafenopin In order to determine the effect of repeated doses of nafenopin and replication of hepatocytes, groups of rats were pre-injected with nafenopin followed by complex as described above and subsequently injected with a second dose of nafenopin at the same dose 1 week later. After an additional week, CAT activity was assayed and found to have risen to a level of 9.3 units/mg.
- ALT serum alanine amino transferase
- targeted foreign gene expression can be made to persist and increase by stimulation of hepatocyte replication through 0 administration of a non-toxic pharmacological agent.
- Regeneration of the liver by hepatocyte replication can be achieved by chemical damage to 5 hepatocytes. This has been demonstrated in a variety of liver specific toxins of which galactosamine is a classic example.
- the p9-12 albCAT plasmid was again complexed with our DNA carrier system.
- 900mg/kg galacto ⁇ samine was injected i.p. into groups of rats, 25 200-240gm at 16, 20, 24 and 39 hours prior to i.v. injection of complex or saline control.
- One week later animals were sacrificed and CAT enzyme activity determined in liver. From these data, the optimal time or pre-incubation of galactosamine was 30 determined to be 24 hours.
- hepatic CAT activity was determined.
- serum ALT values were determined at each time point.
- CAT activity in liver was found to reach peak levels of 6.7 units/mg at 2 weeks and persist at least through 4 weeks after complex and galactosamine administration.
- Serum ALT values demonstrated levels of approximately 1,200 IU, 24 hours after injection of galactosamine indicating that mild hepatocellular injury had occurred.
- CAT activity rose to 9.3 U/mg, 2 weeks after the initial injection.
- a repeated dose of both complex plus nafenopin 1 week after the first injection increased CAT 3vels 14-fold to 78 U/mg when assayed 2 weeks aft r the initial injection.
- Targetable polynucleotide complex alone, or nafenopin alone given at the same two time points resulted in undetectable CAT activity at 2 weeks.
- a time course showed that all animals that received targetable polynucleotide complex plus nafenopin produced CAT levels that remained high through at least 9 weeks.
- Targeted foreign gene expression can be made to increase and persist by stimulation of hepato ⁇ cyte replication by administration of a non-toxic, pharmacological agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3516079A JPH06503714A (en) | 1990-09-25 | 1991-09-23 | Long-term expression of polynucleotides introduced into cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58801390A | 1990-09-25 | 1990-09-25 | |
US588,013 | 1990-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992005250A1 true WO1992005250A1 (en) | 1992-04-02 |
Family
ID=24352098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/006885 WO1992005250A1 (en) | 1990-09-25 | 1991-09-23 | Prolonging expression of polynucleotides introduced into a cell |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0556197A4 (en) |
JP (1) | JPH06503714A (en) |
AU (1) | AU8628291A (en) |
CA (1) | CA2092319A1 (en) |
WO (1) | WO1992005250A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005815A1 (en) * | 1991-09-16 | 1993-04-01 | Syngenix Limited | Synthetic transfection vectors |
EP0538268A1 (en) * | 1990-05-11 | 1993-04-28 | The University Of Connecticut | Targeted protection from cytotoxins |
WO1994002610A1 (en) * | 1992-07-17 | 1994-02-03 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
WO1994004696A1 (en) * | 1992-08-25 | 1994-03-03 | Miles Inc. | Translocation signal facilitated nuclear delivery of macromolecules |
WO1994006922A1 (en) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Method of enhancing and/or prolonging expression of a gene introduced into a cell |
WO1994023050A1 (en) * | 1993-04-05 | 1994-10-13 | University Of Connecticut | Targeted delivery of genes encoding antisense polyribonucleotides |
EP0704221A2 (en) * | 1994-09-29 | 1996-04-03 | Ajinomoto Co., Inc. | A conjugate useful in gene transfer and a method of producing the same |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
WO1997033994A1 (en) * | 1996-03-11 | 1997-09-18 | The Immune Response Corporation | Use of viral cis-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites |
US5851829A (en) * | 1993-07-16 | 1998-12-22 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
WO2000057920A2 (en) * | 1999-03-30 | 2000-10-05 | Medical Research Council | Method for expressing proteins |
US6136792A (en) * | 1994-01-13 | 2000-10-24 | Calydon, Inc. | Prostate specific enhancer polynucleotides and methods of use thereof |
US6159947A (en) * | 1993-06-16 | 2000-12-12 | Aventis Pharma S.A. | Anti-RAS intracellular binding proteins and use thereof |
EP0584279B1 (en) * | 1991-05-14 | 2001-03-14 | The University Of Connecticut | Targeted delivery of genes encoding immunogenic proteins |
US6916918B2 (en) | 1997-08-04 | 2005-07-12 | Cell Genesys, Inc. | Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
-
1991
- 1991-09-23 EP EP19910917379 patent/EP0556197A4/en not_active Withdrawn
- 1991-09-23 CA CA002092319A patent/CA2092319A1/en not_active Abandoned
- 1991-09-23 JP JP3516079A patent/JPH06503714A/en active Pending
- 1991-09-23 WO PCT/US1991/006885 patent/WO1992005250A1/en not_active Application Discontinuation
- 1991-09-23 AU AU86282/91A patent/AU8628291A/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
Cancer Research, Volume 46, issued March 1986, A. FRANCAVILLA et al., "Epidermal Growth Factor and Proliferation in Rat Hepatocytes in Primary Culture Isolated at different times after partial hepatectomy", pages 1318-1323, see entire document. * |
CHEMICAL ABSTRACTS, Volume 87, issued 1977, VARMUS et al., Cellular functions are required for the synthesis and integration of avian saracoma virus-specific DNA", see page 276, column 2, Abstract No. 87:65165y, Cell 11(2), 307-319. * |
Journal of Biological Chemistry, Volume 263, No. 29, issued 15 October 1988, G. WU et al., "Receptor-mediated gene delivery and expression in vivo", pages 14621-14624, see entire document. * |
Journal of Biological Chemistry, Volume 264, No. 29, issued 15 October 1989, WU et al., "Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo", pages 16985-16987, see entire document. * |
Science, Volume 226, issued October 1984, W. FRENCH ANDERSON, "Prospects for Human Gene Therapy", pages 401-409, see entire document. * |
See also references of EP0556197A4 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0538268A1 (en) * | 1990-05-11 | 1993-04-28 | The University Of Connecticut | Targeted protection from cytotoxins |
EP0538268A4 (en) * | 1990-05-11 | 1993-05-12 | The University Of Connecticut | Targeted protection from cytotoxins |
EP0584279B1 (en) * | 1991-05-14 | 2001-03-14 | The University Of Connecticut | Targeted delivery of genes encoding immunogenic proteins |
EP0640350A3 (en) * | 1991-09-16 | 1995-12-13 | Syngenix Ltd | Ceramic particles and their preparation. |
WO1993005815A1 (en) * | 1991-09-16 | 1993-04-01 | Syngenix Limited | Synthetic transfection vectors |
US6153598A (en) * | 1991-09-16 | 2000-11-28 | Syngenix Limited | Synthetic transfection vectors |
US6809082B2 (en) | 1991-09-16 | 2004-10-26 | Molecular Synthetics, Ltd. | Synthetic transfection vectors |
EP0640350A2 (en) * | 1991-09-16 | 1995-03-01 | Syngenix Limited | Ceramic particles and their preparation |
US6072036A (en) * | 1992-07-17 | 2000-06-06 | Dana-Farber Cancer Institute, Inc. | Method of intracellular binding of target molecules |
US6329173B1 (en) | 1992-07-17 | 2001-12-11 | Dana-Farber Cancer Institute, Inc. | Method of intracellular binding target molecules |
US5965371A (en) * | 1992-07-17 | 1999-10-12 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
WO1994002610A1 (en) * | 1992-07-17 | 1994-02-03 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
WO1994004696A1 (en) * | 1992-08-25 | 1994-03-03 | Miles Inc. | Translocation signal facilitated nuclear delivery of macromolecules |
WO1994006922A1 (en) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Method of enhancing and/or prolonging expression of a gene introduced into a cell |
US5656609A (en) * | 1992-09-24 | 1997-08-12 | University Of Connecticut | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine |
AU686614B2 (en) * | 1993-04-05 | 1998-02-12 | Targetech, Inc | Targeted delivery of genes encoding antisense polyribonucleotides |
WO1994023050A1 (en) * | 1993-04-05 | 1994-10-13 | University Of Connecticut | Targeted delivery of genes encoding antisense polyribonucleotides |
US6159947A (en) * | 1993-06-16 | 2000-12-12 | Aventis Pharma S.A. | Anti-RAS intracellular binding proteins and use thereof |
US5851829A (en) * | 1993-07-16 | 1998-12-22 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
US6136792A (en) * | 1994-01-13 | 2000-10-24 | Calydon, Inc. | Prostate specific enhancer polynucleotides and methods of use thereof |
US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
EP0704221A3 (en) * | 1994-09-29 | 1997-03-12 | Ajinomoto Kk | A conjugate useful in gene transfer and a method of producing the same |
US6013526A (en) * | 1994-09-29 | 2000-01-11 | Ajinomoto Co., Inc. | Modified protein for gene transfer and process for producing the same |
EP0704221A2 (en) * | 1994-09-29 | 1996-04-03 | Ajinomoto Co., Inc. | A conjugate useful in gene transfer and a method of producing the same |
WO1996021036A3 (en) * | 1994-12-30 | 1996-09-06 | Viagene Inc | Nucleic acid condensing agents with reduced immunogenicity |
WO1996021036A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
WO1997033994A1 (en) * | 1996-03-11 | 1997-09-18 | The Immune Response Corporation | Use of viral cis-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites |
US6916918B2 (en) | 1997-08-04 | 2005-07-12 | Cell Genesys, Inc. | Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
WO2000057920A3 (en) * | 1999-03-30 | 2001-02-15 | Medical Res Council | Method for expressing proteins |
WO2000057920A2 (en) * | 1999-03-30 | 2000-10-05 | Medical Research Council | Method for expressing proteins |
Also Published As
Publication number | Publication date |
---|---|
EP0556197A1 (en) | 1993-08-25 |
EP0556197A4 (en) | 1994-05-18 |
CA2092319A1 (en) | 1992-03-26 |
AU8628291A (en) | 1992-04-15 |
JPH06503714A (en) | 1994-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6069133A (en) | Targeted delivery of genes encoding interferon | |
WO1992005250A1 (en) | Prolonging expression of polynucleotides introduced into a cell | |
CA2103371C (en) | Targeted delivery of genes encoding secretory proteins | |
US5656609A (en) | Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine | |
US6191257B1 (en) | Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy | |
WO1997030731A2 (en) | Method of preparing polynucleotide-carrier complexes for delivery to cells | |
WO1992019749A1 (en) | Targeted delivery of genes encoding cell surface receptors | |
SK56996A3 (en) | Recombinant obese (ob) proteins | |
AU1612199A (en) | Novel vectors and genes exhibiting increased expression | |
CA2406233A1 (en) | Compositions for drug delivery | |
US5744326A (en) | Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites | |
AU686614B2 (en) | Targeted delivery of genes encoding antisense polyribonucleotides | |
US6479464B1 (en) | Compositions and methods for highly efficient transfection | |
AU735667B2 (en) | Targeted delivery of genes encoding secretory proteins | |
WO1994028151A1 (en) | Gene therapy for haemophilia | |
AU6221198A (en) | Compositions and methods for highly efficient transfection | |
US20040009900A1 (en) | Targeted delivery of genes encoding secretory proteins | |
CN115279419A (en) | Compositions and methods for genome engineering | |
WO1999015687A1 (en) | Multicomponent polynucleotide complex for high efficiency cell transfection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2092319 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991917379 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991917379 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991917379 Country of ref document: EP |